Skip to search formSkip to main contentSkip to account menu

VP025

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
A Novel Phospholipid-Based Drug Formulation, VP025, Modulates Age- and LPS-Induced Microglial Activity in the Rat
Background: A common change that occurs with age in the central nervous system is an increase in microglial-associated… 
2009
2009
The deficit in long-term potentiation induced by chronic administration of amyloid-β is attenuated by treatment of rats with a novel phospholipid-based drug formulation, VP025
2008
2008
Neuroprotective effects of novel phosphatidylglycerol‐based phospholipids in the 6‐hydroxydopamine model of Parkinson's disease
Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating… 
2008
2008
Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition: Implications for Parkinson’s disease
2008
2008
Analysis of the effects of amyloid-beta in rat brain : effect of treatment with a novel anti-inflammatory agent VP025
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License